Merrimack Pharmaceuticals Announces Timing of Third Quarter 2014 Investor Conference Call

CAMBRIDGE, Mass., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. MACK today announced that the company will host its Third Quarter 2014 Investor Conference Call and webcast at 4:30 p.m., Eastern time, on Monday, November 10.  

The call will cover an update on Merrimack's progress as well as a summary of third quarter financials. A press release detailing the information to be discussed on the call will be issued after market close on Monday, November 10. Investors and the general public are invited to listen to the call by dialing (877) 564-1301 (domestic) or (224) 357-2394 (international) five minutes prior to the start of the call and providing the passcode 28850166.

A listen-only webcast of the call will be available in the Investors section of Merrimack's website, http://investors.merrimackpharma.com, and a replay of the call will be archived there for six weeks.

About Merrimack

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack seeks to gain a deeper understanding of underlying cancer biology through its systems biology-based approach and develop new insights, therapeutics and diagnostics to improve outcomes for cancer patients. Merrimack currently has six oncology therapeutics in clinical development and three additional candidates in late stage preclinical development. Merrimack's lead program, MM-398, recently completed a Phase 3 trial in post-gemcitabine pancreatic cancer. Based on the results of this study, Merrimack intends to file a New Drug Application for MM-398 with the U.S. Food and Drug Administration. For more information, please visit Merrimack's website at www.merrimackpharma.com.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.